Heavy! The five major benefits of A-shares are coming! Shi Hammer, the chairman of this A-share company was retained!
Five good things are coming
Recently, the activity of the A-share market has increased significantly. And on November 7, the market ushered in a number of good news.
The first is China's economic recovery, which has just been sharply raised by the International Monetary Fund (IMF) to 5.4% this year.
On November 7, the IMF said that China's real GDP will grow by 5.4% in 2023 and 4.6% in 2024. The current 2023 and 2024 forecasts have been revised upwards by 0.4 percentage points from the October WE projections, reflecting stronger-than-expected growth in the third quarter and a series of recent policy announcements.
According to the IMF, "China's target of implementing the necessary adjustments to the real estate market is welcome." The challenge is to minimize economic costs while managing macro-financial stability risks. Importantly, the recently concluded Central Financial Work Conference announced medium-term priorities, focusing on the risks posed by the real estate sector, local government debt, and small and medium-sized banks, which is welcome. "The IMF suggests that China needs supportive macroeconomic policies to boost economic activity against the backdrop of necessary adjustments to the property sector and structural reforms to address local government debt.
Asked whether China will experience deflation in the near future, IMF First Deputy Managing Director Gita Gopinath said, "We don't see deflation in China, and inflation in China is still within a reasonable range." ”
On the 7th, Wang Jianjun, vice chairman of the China Securities Regulatory Commission, also made the latest statement, saying that the mainland capital market will become more and more open. On the same day, the International Financial Leaders Investment Summit was held in Hong Kong, Wang Jianjun said that the capital market in Chinese mainland itself is a product of reform and opening up, and has been growing and growing by reform and opening up, so the future reform and opening up of the capital market will definitely be the same as the overall situation of China's reform and opening up, and it will inevitably become more and more open.
"At the just-concluded Central Financial Work Conference, it was clearly stated that it is necessary to expand the institutional opening of the financial sector, facilitate cross-border investment and financing, attract more foreign-funded financial institutions and long-term capital to do business in China, further strengthen the interconnection with overseas markets, and implement the new overseas listing regulations.
On the same day, the central bank also had an update. The Financial Market Department of the Central Bank issued a column entitled "Promoting the High-quality Development of China's Financial Market and Helping to Accelerate the Construction of a Financial Power", which pointed out that in the next stage, the People's Bank of China will seriously implement the spirit of the Central Financial Work Conference, accelerate the construction of a modern financial market system with Chinese characteristics, promote the high-quality development of China's financial market, and help accelerate the construction of a financial power.
According to the article, under the principle of ensuring the country's financial and economic security, we will steadily expand the institutional opening up of the financial market in terms of rules, regulations, management, and standards, adhere to the equal emphasis on "bringing in" and "going out", and continuously improve the level of cross-border investment and financing facilitation, so as to inject new impetus and vitality into the high-quality development of the financial market.
According to Blue Whale news, on the afternoon of November 7, the People's Bank of China, the Ministry of Housing and Urban-Rural Development, the State Administration of Financial Supervision and the China Securities Regulatory Commission jointly convened a symposium with several real estate companies to understand the financial situation of the industry and the financing needs of enterprises. It is reported that the participating companies include Vanke, Poly, China Resources, China Shipping, Longfor and Gemdale.
In addition to the above-mentioned benefits, public funds are also actively acting to convey confidence to the capital market. On November 7, CEIBS Fund announced that it would purchase a total of no less than 100 million yuan of its partial stock funds and funds of funds (FOF) in the near future.
Penghua Fund announced on the same day that based on its confidence in the long-term healthy and stable development of China's capital market, it intends to purchase its equity funds by no less than 100 million yuan. So far, nearly 10 public offering officials have recently announced their own purchases. According to statistics, since the end of August, the total self-purchase amount of public funds, securities companies and their asset management has exceeded 3 billion yuan.
Late-night announcement: The chairman was placed in lien
On the evening of November 6, Wohua Pharmaceutical issued an announcement saying that it was recently learned that Zhao Bingxian, the chairman and actual controller of the company, was taken into custody to cooperate with the supervision committee to assist in the investigation.
Wohua Pharmaceutical said in the announcement that the matters involved by Zhao Bingxian have nothing to do with the company, and as of the date of this announcement, the company has not received any notice from the relevant authorities, nor has it received any assistance in the investigation.
As of the end of the third quarter of 2023, Zhao Bingxian's Beijing CSI Wanrong Investment Group held 290 million shares of Wohua Pharmaceutical, with a shareholding ratio of 50.27%, making it the company's largest shareholder, with a corresponding market value of about 1.9 billion yuan.
According to Tianyancha, at present, Zhao Bingxian holds 80% of the equity of Beijing CSI Wanrong Investment Group and is the actual controller of the company.
According to the official website, Wohua Pharmaceutical was established in 2003, focusing on the field of cardiovascular and cerebrovascular Chinese patent medicines, headquartered in Weifang, Shandong, and affiliated to Beijing CSI Wanrong Investment Group Co., Ltd., whose history can be traced back to Wanhetang Pharmaceutical in the Qianlong period of the Qing Dynasty.
The company was listed on the Shenzhen Stock Exchange in 2007, and Wohua Xinkeshu Tablets, Hedan Tablets/Capsules, Cerebrosis Oral Liquid, Gushukang Capsules/Granules, and Yuandu Hanbi Liquid are the exclusive patented products in China, and 93 products have entered the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2022 Edition).
As of the close of trading on November 7, Wohua Pharmaceutical's share price closed down 3.07% at 6.32 yuan per share, with the latest total market value of about 3.648 billion yuan.
Judging from its fundamental performance, the performance of Wohua Pharmaceutical has shown a downward trend. According to the 2022 annual report, the company's revenue was about 1.019 billion yuan, a year-on-year increase of 7.65%; The net profit was about 107 million yuan, a year-on-year decrease of 34.28%. In addition, according to the latest financial report, in the first three quarters of this year, the company achieved revenue of 716 million yuan, a year-on-year decrease of 4.84%; net profit attributable to shareholders of listed companies was 57 million yuan, down 27.45% year-on-year.
Once known as "China Buffett"
According to the official website of Wohua Pharmaceutical, Zhao Bingxian was born in Beijing in November 1963, graduated from Shanghai Jiao Tong University with a master's degree in finance, and has nearly 30 years of experience in investment, mergers and acquisitions, restructuring and listing, and enterprise management. In January 1997, Zhao Bingxian published the book "Theory of Capital Operation", which was the first monograph in China to systematically discuss capital operation and investment banking, and was rated as one of the top ten bestsellers in China in 1997 (it is rumored that nearly two million copies were sold in the book market).
Regarding his business history, in 1991, Zhao Bingxian founded and served as the chairman and general manager of Beijing CSI Wanrong Investment Group, the chairman of Beijing CSI Wanrong Pharmaceutical Investment Group, the chairman of Wohua Pharmaceutical, and the director of Luolai Life (002293). In February 2002, he served as the chairman of Wohua Pharmaceutical.
It is worth noting that on October 27 this year, Luolai Life issued an announcement saying that Zhao Bingxian applied for resignation as a director of the sixth board of directors of the company for personal reasons, and will no longer hold any position in the company after his resignation.
Capital market sources said that when Luo Lai Life released Zhao Bingxian's resignation report, his personal should have been in a state of lien, otherwise there may be a situation where directors cannot attend the company's review of the third quarterly report.
Zhao Bingxian has been dancing in the capital circle for a long time, concentrating on capital operation, and is quite famous in the capital market. Since 2000, it has helped Tong Ren Tang Technology to successfully list in Hong Kong through CSI Wanrong, so it has become famous in the industry.
Since then, Zhao Bingxian has directly invested in 7 companies in the name of an individual or company, and helped many companies successfully go public, so he was once known as "China's Buffett".
In 2010, Zhao Bingxian was accused of domestic violence, extramarital affairs, etc., and fell into a divorce dispute with his wife, which caused a sensation.
Previous Review
Sudden bearishness! More than 50,000 shareholders panicked! The Securities Regulatory Commission took action and filed a case! Vanke has a bombshell news, what's the situation?